<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874237</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-004-107</org_study_id>
    <secondary_id>February 26, 2009</secondary_id>
    <nct_id>NCT00874237</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine Thorough QT/QTc Study</brief_title>
  <official_title>Thorough QT/QTc Study of StaccatoÂ® Loxapine for Inhalation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present Phase 1 study was to assess the cardiac safety of Staccato
      Loxapine administered to healthy volunteers in a 3 period crossover study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To assess the maximum effect of Staccato Loxapine on cardiac
      repolarization (QTc interval duration) at the anticipated maximum clinical dose compared to
      placebo in healthy volunteers.

      Secondary Objective: To assess the QTc versus loxapine concentration relationship following
      treatment with Staccato Loxapine in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind, double dummy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
    <description>Largest of the upper CIs of the time matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time matched placebo subtraction for ADASUVE treatment at 12 prespecified post inhalation times</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.</measure>
    <time_frame>24 hours</time_frame>
    <description>QTcI change at the median loxapine concentration (32.2 mcg/mL) based on nonlinear regression of QTcI versus log of time matched serum loxapine concentrations. This analysis looks for repolarization versus concentration relationship in a positive or negative thorough QT/QTc study result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and % of Subjects With QTcI &gt; 450 ms</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
    <description>Numbers and Percents of Subjects with QTcI exceeding 450 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and % of Subjects With QTcI &gt; 480 ms</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
    <description>Numbers and Percents of Subjects with QTcI exceeding 480 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and % of Subjects With QTcI Change &gt; 30 ms</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
    <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers and % of Subjects With QTcI Change &gt; 60 ms</measure>
    <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
    <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</measure>
    <time_frame>1, 1.5, 2, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
    <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec ant any of the 9 predetermined time points</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Thorough QT/QTc Study</condition>
  <arm_group>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled loxapine</intervention_name>
    <description>Inhaled Staccato Loxapine 10 mg single dose</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
    <other_name>ADASUVE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo</intervention_name>
    <description>Inhaled Staccato placebo single dose</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral moxifloxacin</intervention_name>
    <description>Oral moxifloxacin 400 mg</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <description>Oral placebo similar in appearance to moxifloxacin 400 mg</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are in good general health and agree to use a medically acceptable and
             effective birth control method throughout the study.

        Exclusion Criteria:

          -  Subjects who have taken prescription or nonprescription medication within 5 days of
             treatment,

          -  Subjects who have had an acute illness within the last 5 days of treatment,

          -  Subjects who are smokers, OR

          -  Subjects who have an ECG abnormality at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall R. Stoltz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Spyker DA, Voloshko P, Heyman ER, Cassella JV. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J Clin Pharmacol. 2014 Jun;54(6):665-74. doi: 10.1002/jcph.257. Epub 2014 Jan 22.</citation>
    <PMID>24375070</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>October 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staccato loxapine</keyword>
  <keyword>QT/QTc</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>Thorough QT/QTc study</keyword>
  <keyword>ADASUVE</keyword>
  <keyword>inhaled loxapine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsDoc@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>132 subjects were screened.</recruitment_details>
      <pre_assignment_details>Of the 132 subjects who were screened for the study, 69 did not meet criteria, 5 withdrew consent, 1 no show, 9 enrollment full.
48 (36.4%) were randomized and received at least 1 dose of study medication, and 46 completed the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence ABC</title>
          <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence ACB</title>
          <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence BCA</title>
          <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence BAC</title>
          <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence CAB</title>
          <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
        </group>
        <group group_id="P6">
          <title>Treatment Sequence CBA</title>
          <description>Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects Treated</title>
          <description>All 6 treatment sequences</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.854" spread="13.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</title>
        <description>Largest of the upper CIs of the time matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time matched placebo subtraction for ADASUVE treatment at 12 prespecified post inhalation times</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
        <population>QT population (all patients receiving both placebo and 10 mg inhaled loxapine. LSM and CI statistics were based on the individual (within subject) corrected differences between Adasuve and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Loxapine 10 mg vs Placebo Crossover Subjects</title>
            <description>Largest upper 95% Upper Confidence Bound (msec) for Inhaled loxapine QTcI Differences from Placebo in Change from Predose Baseline
All upper CIs &lt; 10 msec establishes this as a negative Thorough QT/QTc Study as defined in the ICH E14 guideline, 2005,</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo</title>
          <description>Largest of the upper CIs of the time matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time matched placebo subtraction for ADASUVE treatment at 12 prespecified post inhalation times</description>
          <population>QT population (all patients receiving both placebo and 10 mg inhaled loxapine. LSM and CI statistics were based on the individual (within subject) corrected differences between Adasuve and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
          <units>mseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.418" lower_limit="3.083" upper_limit="7.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.</title>
        <description>QTcI change at the median loxapine concentration (32.2 mcg/mL) based on nonlinear regression of QTcI versus log of time matched serum loxapine concentrations. This analysis looks for repolarization versus concentration relationship in a positive or negative thorough QT/QTc study result.</description>
        <time_frame>24 hours</time_frame>
        <population>QT + PK Population (all subjects receiving placebo and loxapine who provided QTc and pharmacokinetic data).
LSM and CI statistics were based on the individual (within subject) corrected differences between loxapine and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Loxapine 10 mg</title>
            <description>Largest upper 95% Upper Confidence Bound (msec) for Inhaled loxapine QTcI Differences from Placebo in Change from Predose Baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.</title>
          <description>QTcI change at the median loxapine concentration (32.2 mcg/mL) based on nonlinear regression of QTcI versus log of time matched serum loxapine concentrations. This analysis looks for repolarization versus concentration relationship in a positive or negative thorough QT/QTc study result.</description>
          <population>QT + PK Population (all subjects receiving placebo and loxapine who provided QTc and pharmacokinetic data).
LSM and CI statistics were based on the individual (within subject) corrected differences between loxapine and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
          <units>mseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.238" lower_limit="2.859" upper_limit="5.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers and % of Subjects With QTcI &gt; 450 ms</title>
        <description>Numbers and Percents of Subjects with QTcI exceeding 450 ms</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
        <population>QT Population (all subjects receiving placebo and inhaled loxapine and providing QT data</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Loxapine 10 mg</title>
            <description>All subjects who received inhaled loxapine 10 mg (and oral) placebo and provided QTcI data</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo</title>
            <description>All subjects who received inhaled (and oral) placebo and provided QTcI data</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and % of Subjects With QTcI &gt; 450 ms</title>
          <description>Numbers and Percents of Subjects with QTcI exceeding 450 ms</description>
          <population>QT Population (all subjects receiving placebo and inhaled loxapine and providing QT data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers and % of Subjects With QTcI &gt; 480 ms</title>
        <description>Numbers and Percents of Subjects with QTcI exceeding 480 ms</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
        <population>QT Population (all subjects receiving placebo and inhaled loxapine and providing QT data</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Loxapine 10 mg</title>
            <description>All subjects who received inhaled loxapine 10 mg (and oral) placebo and provided QTcI data</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo</title>
            <description>All subjects who received inhaled (and oral) placebo and provided QTcI data</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and % of Subjects With QTcI &gt; 480 ms</title>
          <description>Numbers and Percents of Subjects with QTcI exceeding 480 ms</description>
          <population>QT Population (all subjects receiving placebo and inhaled loxapine and providing QT data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers and % of Subjects With QTcI Change &gt; 30 ms</title>
        <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
        <population>QT Population (all subjects receiving placebo and inhaled loxapine and providing QT data</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Loxapine 10 mg</title>
            <description>All subjects who received inhaled loxapine 10 mg (and oral) placebo and provided QTcI data</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo</title>
            <description>All subjects who received inhaled (and oral) placebo and provided QTcI data</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and % of Subjects With QTcI Change &gt; 30 ms</title>
          <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms</description>
          <population>QT Population (all subjects receiving placebo and inhaled loxapine and providing QT data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers and % of Subjects With QTcI Change &gt; 60 ms</title>
        <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms</description>
        <time_frame>1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours</time_frame>
        <population>QT Population (all subjects receiving placebo and inhaled loxapine and providing QT data</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Loxapine 10 mg</title>
            <description>All subjects who received inhaled loxapine 10 mg (and oral) placebo and provided QTcI data</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Placebo</title>
            <description>All subjects who received inhaled (and oral) placebo and provided QTcI data</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and % of Subjects With QTcI Change &gt; 60 ms</title>
          <description>Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms</description>
          <population>QT Population (all subjects receiving placebo and inhaled loxapine and providing QT data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</title>
        <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec ant any of the 9 predetermined time points</description>
        <time_frame>1, 1.5, 2, 2.5, 3, 5, 8, 12, and 24 hr</time_frame>
        <population>All subjects who completed both Inhaled placebo + oral placebo and moxifloxacin 400 mg + Inhaled placebo.
LSM and CI statistics were based on the individual (within subject) corrected differences between moxifloxacin and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Moxifloxacin vs Placebo Crossover Subjects</title>
            <description>Largest lower 95% Upper Confidence Bound (msec) for moxifloxacin QTcI Differences from Placebo in Change from Predose Baseline
Lower CI &gt; 5 msec at 1 or more time points establishes sensitivity of the QTc assay for the study</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)</title>
          <description>A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec ant any of the 9 predetermined time points</description>
          <population>All subjects who completed both Inhaled placebo + oral placebo and moxifloxacin 400 mg + Inhaled placebo.
LSM and CI statistics were based on the individual (within subject) corrected differences between moxifloxacin and placebo exposures per ICH Guideline E14 for a thorough QT study.</population>
          <units>mseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.356" lower_limit="5.825" upper_limit="10.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Adverse events (AEs) were assessed predose and at 14 prespecified time points as well as whenever spontaneously reported by the subjects</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Loxapine 10 mg</title>
          <description>Inhaled Staccato Loxapine 10 mg single dose Oral placebo
Inhaled loxapine: Inhaled Staccato Loxapine 10 mg single dose
Oral placebo: Oral placebo</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Inhaled Staccato placebo single dose Oral placebo
Inhaled placebo: Inhaled Staccato placebo single dose
Oral placebo: Oral placebo</description>
        </group>
        <group group_id="E3">
          <title>Oral Moxifloxacin</title>
          <description>Inhaled Staccato placebo single dose Oral moxifloxacin 400 mg
Inhaled placebo: Inhaled Staccato placebo single dose
Oral moxifloxacin: Oral Moxifloxacin 400 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="47"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis, contact</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The highest approved inhaled loxapine dose of 10 mg was studied. Supratherapeutic doses were not evaluated because of tolerability concerns in healthy subjects. The inclusion of only healthy subjects is likewise a limitation of this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7777</phone>
      <email>jcassella@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

